Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Xuanzhu Biopharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -28.41%.
As of today (2026-08-10), Xuanzhu Biopharmaceutical Co's WACC % is 10.65%. Xuanzhu Biopharmaceutical Co's ROIC % is -26.10% (calculated using TTM income statement data).
Xuanzhu Biopharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Xuanzhu Biopharmaceutical Co (HKSE:02575) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Xuanzhu Biopharmaceutical Co's WACC % is 10.65%. Xuanzhu Biopharmaceutical Co's ROIC % is -26.10% (calculated using TTM income statement data).
Xuanzhu Biopharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Xuanzhu Biopharmaceutical Co ROIC % Related Terms
Xuanzhu Biopharmaceutical Co ROIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co ROIC % Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
ROIC %
-39.65
-67.25
-26.37
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
ROIC %
0.00
-27.01
-105.93
-23.63
-28.41
HKSE:02575 vs ZTS: ROIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co ROIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's ROIC % distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's ROIC % falls into.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a ROIC % of -28.41% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's ROIC % too high?
Xuanzhu Biopharmaceutical Co's current ROIC % is -28.41%. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's ROIC % compare to ZTS?
Xuanzhu Biopharmaceutical Co's ROIC % of -28.41% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.40, based on 990 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current ROIC % is -28.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current ROIC % of -28.41%. The current ROIC % is -28.41%. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current ROIC % is -28.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for HKSE:02575
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02575 has been successfully added to your 
